Novartis AG (NYSE:NVS) has been assigned an average recommendation of “Hold” from the nineteen research firms that are currently covering the company. Two investment analysts have rated the stock with a sell recommendation, eleven have given a hold recommendation and six have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $80.42.
A number of research firms recently issued reports on NVS. JPMorgan Chase & Co. reiterated a “neutral” rating on shares of Novartis AG in a research report on Tuesday. Vetr cut shares of Novartis AG from a “strong-buy” rating to a “buy” rating and set a $78.32 price objective for the company. in a research report on Thursday, April 6th. Cowen and Company cut shares of Novartis AG from an “outperform” rating to a “market perform” rating and decreased their price target for the company from $87.00 to $77.00 in a research report on Wednesday, April 5th. Goldman Sachs Group Inc restated a “neutral” rating on shares of Novartis AG in a research report on Wednesday, March 22nd. Finally, Liberum Capital assumed coverage on shares of Novartis AG in a research report on Thursday, March 9th. They issued a “buy” rating for the company.
A number of institutional investors have recently modified their holdings of the company. Howe & Rusling Inc. raised its position in shares of Novartis AG by 192.2% in the first quarter. Howe & Rusling Inc. now owns 1,341 shares of the company’s stock worth $100,000 after buying an additional 882 shares in the last quarter. Sowell Financial Services LLC acquired a new position in shares of Novartis AG during the fourth quarter worth $116,000. Zions Bancorporation raised its position in shares of Novartis AG by 21.0% in the fourth quarter. Zions Bancorporation now owns 1,656 shares of the company’s stock worth $120,000 after buying an additional 287 shares in the last quarter. Mosaic Family Wealth LLC raised its position in shares of Novartis AG by 11.2% in the third quarter. Mosaic Family Wealth LLC now owns 1,886 shares of the company’s stock worth $149,000 after buying an additional 190 shares in the last quarter. Finally, Integrated Wealth Counsel LLC raised its position in shares of Novartis AG by 13.8% in the third quarter. Integrated Wealth Counsel LLC now owns 1,998 shares of the company’s stock worth $158,000 after buying an additional 242 shares in the last quarter. Hedge funds and other institutional investors own 9.82% of the company’s stock.
Shares of Novartis AG (NYSE:NVS) traded down 0.30% on Tuesday, hitting $73.40. 2,326,290 shares of the stock were exchanged. Novartis AG has a one year low of $66.93 and a one year high of $83.58. The firm has a market capitalization of $174.26 billion, a PE ratio of 26.21 and a beta of 0.73. The company has a 50-day moving average price of $74.50 and a 200-day moving average price of $73.40.
Novartis AG (NYSE:NVS) last released its quarterly earnings data on Wednesday, January 25th. The company reported $1.12 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $1.12. The business earned $12.32 billion during the quarter, compared to analysts’ expectations of $12.44 billion. Novartis AG had a net margin of 13.80% and a return on equity of 15.37%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period in the prior year, the company earned $1.14 EPS. Equities research analysts expect that Novartis AG will post $4.69 earnings per share for the current year.
Novartis AG Company Profile
Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company’s segments include Innovative Medicines, Sandoz, Alcon and Corporate activities.
Receive News & Ratings for Novartis AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis AG and related companies with MarketBeat.com's FREE daily email newsletter.